Thus, we assessed dacomitinib, a panHER inhibitor with broad specificity, in a panel of 27 HNSCC and showed HNSCC cell lines are more sensitive to it than the small molecule anti-EGFR tyrosine kinase inhibitor erlotinib and the anti-EGFR antibody cetuximab in proliferation assays (see Figure 1) and using a subset of ten cell lines we showed that dacomitinib was more effective at blocking EGFR signaling than cetuximab. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.